Early initiation of Eslicarbazepine acetate therapy appears to result in better control of status epilepticus, as deciphered from a recent study. Yaroslav Winter et al. sought to assess the Eslicarbazepine acetate's effectiveness and safety in the treatment of refractory status epilepticus.

The Mainz Epilepsy Registry (MAINZ-EPIREG) provided information on the safety and effectiveness of Eslicarbazepine acetate (a novel sodium channel blocker) for the management of refractory status epilepticus.

To determine status interruption predictors, logistic regression was used. Eslicarbazepine acetate was used to treat a total of 64 individuals with distant symptomatic refractory status epilepticus. Idiopathic generalized epilepsy instances weren't incorporated. Notably, 61.4 ± 11.0 years was the average age. Prior to the advent of Eslicarbazepine acetate, three anti-seizure medications were typically administered. Before administering Eslicarbazepine acetate, an average of 2 days had passed since the start of status epilepticus.

In the event of non-response, the starting dose of 800 mg/day was raised to a maximum daily dose of 1,600 mg. Within 48 hours after receiving Eslicarbazepine acetate treatment in 29 of 64 individuals (45.3%), the status epilepticus could be interrupted. As found, 62% of subjects (15/23) with post-stroke epilepsy had their status epilepticus under control. Early Eslicarbazepine acetate treatment commencement was an independent indicator of status epilepticus control.

Five individuals (7.8%) experienced hyponatraemia. No other side effects were noticed.  Eslicarbazepine acetate can be utilized as an additional therapy to combat recalcitrant status epilepticus. Post-stroke epilepsy subjects had the best response. Additionally, early use of Eslicarbazepine acetate seems to be associated with improved status epilepticus management. Besides a few instances of hyponatremia, no additional adverse events were found.